Avalo Therapeutics, Inc.
AVTX · NASDAQ
Bulios Fair Price
$14.76
8.7% downside
Current Price
$16.17
According to Bulios Fair Price, AVTX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Avalo Therapeutics is an American biopharmaceutical company focused on developing medicines for the treatment of cancer and autoimmune diseases. The company specializes in utilizing innovative therapeutic approaches, including immunotherapy and targeted therapy, to identify and treat various types of cancer. Their research and development efforts are aimed at discovering new drug compounds and therapeutic methods that could improve the lives of patients and bring new hope to the field of cancer treatment. Avalo Therapeutics shares could be an interesting choice for investors looking for opportunities in the biotechnology sector and drug development for cancer.
Sector
Healthcare
Industry
Biotechnology
CEO
Garry A. Neil
Employees
33
Headquarters
Wayne
Upcoming events
Earnings
Upcoming earnings report